Critical Limb Ischemia (CLI) Clinical Trial
Official title:
Phase I, Non-Randomized, Feasibility Study for the Use of Bone Marrow Cell Concentrate Prepared Using the Magellan System for the Treatment of Critical Limb Ischemia
The purpose of this study is to evaluate the safety of administration of marrow-derived autologous hematopoietic stem cells (HSC) concentrate and platelet-rich plasma (PRP) gel for the treatment of Critical Limb Ischemia (CLI).
Critical limb ischemia (CLI) continues to be an important cause of atherosclerotic morbidity
and mortality despite conventional therapies. Modulation of angiogenesis is a promising
alternative to surgical revascularization. Trials of isolated angiogenic growth factor
therapies using recombinant proteins or gene transfer have been conducted, but with
disappointing results because it is unlikely that a single angiogenic factor is solely or
even primarily responsible for angiogenesis. Emerging stem cell therapies represent a new
approach to the modulation of angiogenesis. Pluripotent hematopoietic stem cells (HSC) hold
promise because they can reproduce a pro-angiogenic milieu in the ischemic limb rather than
upregulate a single angiogenic factor.
For this CLI study, the Magellan® System is utilized for the preparation of autologous cell
concentrate at the point of care. The bone marrow aspirate is obtained from the patient and
concentrated with the cell concentration kit, and delivered intramuscularly to the affected
limb for the treatment of impaired ischemic tissue in order to improve perfusion, reduce
pain and revascularize tissues in patients who have inadequate tissue blood flow,
prohibitive medical comorbidities, or failed previous treatments for revascularization for
the prevention of amputation.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02287974 -
Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03006770 -
Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
|
Phase 3 | |
| Completed |
NCT00987363 -
Intraarterial Infusion of Autologous Bone Marrow in Diabetic Patients With Chronic Ischemia of Lower Limbs (CLI) no Revascularization
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02538978 -
Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System
|
Phase 3 | |
| Completed |
NCT01408381 -
Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-diabetic Patients With Critical Limb Ischemia (CLI).
|
Phase 2 | |
| Active, not recruiting |
NCT05208905 -
LIFE-BTK PK Sub-study
|
N/A | |
| Recruiting |
NCT04849325 -
IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease
|
N/A | |
| Completed |
NCT01257776 -
Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04227899 -
LIFE-BTK Randomized Controlled Trial
|
N/A | |
| Terminated |
NCT03111238 -
The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM
|
Phase 3 | |
| Terminated |
NCT03174522 -
The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
|
Phase 3 | |
| Available |
NCT03886506 -
Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
|
||
| Available |
NCT03746899 -
Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI)
|